Watch Demo

Brain Cancer Diagnostics Market Research Report by Test Type, Brain Cancer Type, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Brain Cancer Diagnostics Market Research Report by Test Type, Brain Cancer Type, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:142

  • Report ID:6388749

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Brain Cancer Diagnostics Market Research Report by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and PET Scan), Brain Cancer Type, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Brain Cancer Diagnostics Market size was estimated at USD 766.54 million in 2022 and expected to reach USD 881.76 million in 2023, projecting growth at a CAGR of 13.09% to reach USD 2,052.15 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Brain Cancer Diagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Brain Cancer Diagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Brain Cancer Diagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Brain Cancer Diagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Brain Cancer Diagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Test Type, the market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap.

Based on Brain Cancer Type, the market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Brain Cancer Diagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Brain Cancer Diagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Brain Cancer Diagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Brain Cancer Diagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Brain Cancer Diagnostics Market, including Abbott Laboratories, Associated Regional and University Pathologists, Inc., Becton, Dickinson and Company, Bristol Myers Squibb Co, F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Koninklijke Philips N.V., NantOmics, NeoGenomics Laboratories, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Brain Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Brain Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Brain Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the United States Brain Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the United States Brain Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the United States Brain Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the United States Brain Cancer Diagnostics Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of brain cancer
5.1.1.2. Favorable reimbursement policies
5.1.2. Restraints
5.1.2.1. Heavy costs associated with diagnosis
5.1.3. Opportunities
5.1.3.1. Technological advancement and interaction of AI in diagnostics devices
5.1.4. Challenges
5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Brain Cancer Diagnostics Market, by Test Type
6.1. Introduction
6.2. Magnetic Resonance Imaging
6.3. Magnetic Resonance Spectroscopy
6.4. PET Scan
6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type
7.1. Introduction
7.2. Acoustic Neuroma
7.3. Astrocytomas
7.4. Chordomas
7.5. Ependymomas

8. California Brain Cancer Diagnostics Market
8.1. Introduction

9. Florida Brain Cancer Diagnostics Market
9.1. Introduction

10. Illinois Brain Cancer Diagnostics Market
10.1. Introduction

11. New York Brain Cancer Diagnostics Market
11.1. Introduction

12. Ohio Brain Cancer Diagnostics Market
12.1. Introduction

13. Pennsylvania Brain Cancer Diagnostics Market
13.1. Introduction

14. Texas Brain Cancer Diagnostics Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. Associated Regional and University Pathologists, Inc.
16.3. Becton, Dickinson and Company
16.4. Bristol Myers Squibb Co
16.5. F. Hoffmann-La Roche AG
16.6. Fujifilm Corporation
16.7. GE Healthcare
16.8. Hitachi, Ltd.
16.9. Hologic, Inc.
16.10. Illumina, Inc.
16.11. Invitae Corporation
16.12. Koninklijke Philips N.V.
16.13. NantOmics
16.14. NeoGenomics Laboratories, Inc.
16.15. Siemens Healthineers AG
16.16. Thermo Fisher Scientific, Inc.

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TEST TYPE, 2030
FIGURE 12. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2030 (%)
FIGURE 17. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY BRAIN CANCER TYPE, 2030
FIGURE 19. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, 2018-2030 (USD MILLION)
FIGURE 23. CALIFORNIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 24. FLORIDA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 25. ILLINOIS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 26. NEW YORK BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 27. OHIO BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. PENNSYLVANIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. TEXAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 31. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 32. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. CALIFORNIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 24. CALIFORNIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 25. CALIFORNIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 26. FLORIDA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 27. FLORIDA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 28. FLORIDA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 29. ILLINOIS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 30. ILLINOIS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 31. ILLINOIS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 32. NEW YORK BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 33. NEW YORK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 34. NEW YORK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 35. OHIO BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 36. OHIO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 37. OHIO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 38. PENNSYLVANIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 39. PENNSYLVANIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 40. PENNSYLVANIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 41. TEXAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 42. TEXAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 43. TEXAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 45. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 46. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 47. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 48. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 49. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 50. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 51. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 52. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 53. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 54. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 55. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Associated Regional and University Pathologists, Inc.
Becton, Dickinson and Company
Bristol Myers Squibb Co
F. Hoffmann-La Roche AG
Fujifilm Corporation
GE Healthcare
Hitachi, Ltd.
Hologic, Inc.
Illumina, Inc.
Invitae Corporation
Koninklijke Philips N.V.
NantOmics
NeoGenomics Laboratories, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.